

## SCIENTIFIC PROGRAM

### SESSION LECTURE

No. 59

Immunotherapy and Biotherapy

Room: 311B

Co-Chairs: Zhigang Tian



Eric Vivier



Day 3 October 29<sup>th</sup> (Monday) 8:30 – 12:00

Time	Speaker	Title
8:30-9:00	<b>Zhigang Tian</b> <i>University of Science and Technology of China, China</i>	NK cell Exhaustion and Reversal by Checkpoint Blockade
9:00-9:30	<b>Eric Vivier</b> <i>Aix Marseille University, France</i>	Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
9:30-10:00	<b>Zhinan Yin</b> <i>Jinan University, China</i>	Clinical application of allogenic gammadelta T cells against late-stage cancer and drug-resistant TB
10:00-10:30	<b>Tea Break</b>	
10:30-11:00	<b>Sophie Ugolini</b> <i>Aix Marseille University, France</i>	Neuroendocrine regulation of immunity
11:00-11:30	<b>Weidong Han</b> <i>Chinese PLA General Hospital, China</i>	Dual-target CAR T cell therapy in B cell malignancies

**Zhigang Tian**

[tzg@ustc.edu.cn](mailto:tzg@ustc.edu.cn)

Professor in School of Life Sciences, University of Science and Technology of China. Academician of Chinese Academy of Engineering. Professor Tian's research programme focuses on understanding the basic knowledge and clinical study of NK cells, particularly liver-resident NK cells, cytokine-producing NK cell subsets, and NK cell-based immunotherapy.

**Eric Vivier**

[vivier@ciml.univ-mrs.fr](mailto:vivier@ciml.univ-mrs.fr)

Eric Vivier is Co-founder and Chief Scientific Officer of the biopharmaceutical company Innate pharma, a pioneer of global immunotherapy. Eric Vivier opened the way for the development of new therapeutic strategies against cancer and inflammatory diseases.

**Zhinan Yin**

[Zhinan.yin@yale.edu](mailto:Zhinan.yin@yale.edu)

Professor Yin's research programme focuses on the molecular mechanisms of gammadelta T cells for their differentiation and functions against tumor and pathogen infection. He is also investigating the cytokine network on HFD-induced obesity and thermogenesis program, and exploring the active compound from Chinese medicine.

**Sophie Ugolini**

[ugolini@ciml.univ-mrs.fr](mailto:ugolini@ciml.univ-mrs.fr)

Director of Research (DR-INSERM) at the Centre d'immunologie de Marseille-Luminy (CIML). Her research interests include biology of inflammation, innate immunity, immune responses to pathogens and tumors.

**Weidong Han**

[hanwdrsw69@yahoo.com](mailto:hanwdrsw69@yahoo.com)

Professor Han's research programme focuses on clinical translation of tumor immunotherapy such as chimeric antigen receptor-engineered T cell therapy. In addition, he also has interest in tumor-resistant molecular mechanism research, epigenetic regulation and clinical translation of immune checkpoint blockade agents.